scholarly journals “Low Echoic Area” around stent after bare and drug-coated stenting or stent graft placement for superficial femoral artery disease

2021 ◽  
Vol 9 ◽  
pp. 2050313X2110145
Author(s):  
Yoshimitsu Soga ◽  
Kenji Ando
Keyword(s):  
Stent Graft ◽  
Femoral Artery ◽  
Superficial Femoral Artery ◽  
Drug Eluting Stent ◽  
Drug Eluting ◽  
Cook Medical ◽  
Artery Disease ◽  
Zilver Ptx ◽  
Cordis Corporation

Restenosis after stent implantation in femoropopliteal lesions is still big issue. However, restenosis has been reduced by the recent new drug-eluting stent “Eluvia” (Boston Scientific, Marlborough, MA, USA). However, it was reported that “low echoic area (LEA)” finding around stent by ultrasound that they called “aneurysmal degeneration,” but no blood flow was identified outside the stent was confirmed after Eluvia implantation. In this report, we describe the similar findings that were observed after other types of stents (S.M.A.R.T. bare-nitinol stent (Cordis Corporation, Hialeah, FL, USA), Zilver PTX drug-coated stent (Cook Medical, Bloomington, IN, USA), and Viabahn stent graft (W. L. Gore & Associates, Newark, Delaware, USA)) for superficial femoral artery disease. These findings did not change to “aneurysmal change” during the follow-up.

Abstract 13748: Predictors of Yellow Neointima After Stent Implantation in the Superficial Femoral Artery

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Takuya Tsujimura ◽  
Takayuki Ishihara ◽  
Osamu Iida ◽  
Shin Okamoto ◽  
Kiyonori Nanto ◽  
...  
Keyword(s):  
Femoral Artery ◽  
Superficial Femoral Artery ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Patient Characteristics ◽  
Bare Metal Stent ◽  
Drug Eluting Stent ◽  
Drug Eluting ◽  
Neointimal Coverage

Background: Neoatherosclerosis is known to occur after coronary stenting, but whether it occurs following stenting in the superficial femoral artery (SFA) remains unknown. Methods: This study comprised angioscopic evaluations of 149 stents implanted in the 102 SFA lesions from 92 patients from April 2012 to September 2014. Complete neointimal coverage (defined as struts fully embedded and invisible) was found in 87 stents in the 67 native lesions from the 61 patients. We compared characteristics between the cases with (23 stents, 26%) and without yellow neointima (YN) at the site of complete neointimal coverage, and evaluated the predictors of YN. Results: Median follow-up duration was significantly longer in the YN(+) than YN(-) group (370 [interquartile range: 282-884] days vs. 350 [95-394] days, P<0.001), while patient characteristics, medication use, rate of drug-eluting stent and bare-metal stent use (48% vs. 50%, P=1.0), and lesion and procedural characteristics were similar between them. Low-density lipoprotein cholesterol (LDL-C) level at intervention was higher in the YN(+) than YN(-) group (109±25 mg/dL vs. 97±25 mg/dL, P=0.049). At angioscopic follow-up, LDL and total cholesterol (TC) levels were higher in the YN(+) than YN(-) group (109±27 mg/dL vs. 97±25 mg/dL, P= 0.046; and 188±33 mg/dL vs. 172±34 mg/dL, P=0.048, respectively). Conclusions: YN was associated with the degree of dyslipidemia, suggesting the presence of neoatherosclerosis in the SFA following stenting.

Cost-Effectiveness Analysis of Drug Coated Balloon vs. Drug Eluting Stent in the Superficial Femoral Artery

2017 ◽  
Vol 41 ◽  
pp. 24 ◽  
Author(s):  
Natalie D. Sridharan ◽  
Aureline Boitet ◽  
Kenneth Smith ◽  
Kathy Noorbakhsh ◽  
Efthymios Avgerinos ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Femoral Artery ◽  
Superficial Femoral Artery ◽  
Cost Effectiveness Analysis ◽  
Drug Eluting Stent ◽  
Effectiveness Analysis ◽  
Drug Eluting ◽  
Drug Coated Balloon

scholarly journals Sustained drug retention after paclitaxel-coated balloon angioplasty for superficial femoral artery disease: Follow-up intravascular imaging

2020 ◽  
Vol 8 ◽  
pp. 2050313X2090782
Author(s):  
Norihiro Kobayashi ◽  
Keisuke Hirano ◽  
Masahiro Yamawaki ◽  
Motoharu Araki ◽  
Tsuyoshi Sakai ◽  
...  
Keyword(s):  
Frequency Domain ◽  
Femoral Artery ◽  
Balloon Angioplasty ◽  
Superficial Femoral Artery ◽  
Optical Frequency ◽  
Optical Frequency Domain Imaging ◽  
Drug Retention ◽  
Artery Disease ◽  
The Right

A 63 year-old woman with claudication underwent endovascular therapy for diffuse stenosis of the right superficial femoral artery in our hospital. We performed paclitaxel-coated balloon angioplasty using the IN.PACT™ Admiral™ and achieved acceptable results. After 42 days, we performed follow-up optical frequency domain imaging for the right superficial femoral artery lesion treated with paclitaxel-coated balloon and observed several high-intensity regions with attenuation on the lumen surface. Sustained drug availability is a notable characteristic of paclitaxel-coated balloon. To the best of our knowledge, this is the first report on the visualization of sustained drug retention on the lumen surface using follow-up optical frequency domain imaging after paclitaxel-coated balloon angioplasty in a human patient with superficial femoral artery disease.

Provisional Stenting Using the Zilver PTX Drug-Eluting Stent After Drug-Coated Balloon Angioplasty: Initial Experience From the Double Drug Dose “3D” Study

2019 ◽  
Vol 27 (1) ◽  
pp. 34-41
Author(s):  
Fabrizio Fanelli ◽  
Alessandro Cannavale ◽  
Michele Citone ◽  
Mariangela Santoni ◽  
Marianna Gazzetti ◽  
...  
Keyword(s):  
Primary Patency ◽  
Drug Eluting Stent ◽  
Secondary Patency ◽  
Systemic Complications ◽  
Aneurysm Formation ◽  
Drug Eluting ◽  
Provisional Stenting ◽  
Zilver Ptx ◽  
Drug Coated Balloon

Purpose: To explore the provisional use of a drug-eluting stent (DES) after suboptimal drug-coated balloon (DCB) angioplasty in complex, calcified femoropopliteal lesions. Materials and Methods: A prospective, single-center, investigator-initiated pilot study enrolled 15 patients (mean age 71.3 years; 9 men) with symptomatic stenosis (n=6) or occlusion (n=9) of the native superficial femoral and/or proximal popliteal arteries who experienced suboptimal DCB dilation despite postdilation. Lesion characteristics were evaluated with computed tomography angiography and duplex ultrasound confirmed by intravascular ultrasound. Follow-up included clinical and imaging evaluations as well as blood tests to monitor inflammatory markers. Endpoints included systemic inflammation, acute/chronic thrombosis, aneurysm formation, and mortality. Results: Provisional stenting was required for residual stenosis >50% in 4 cases and flow-limiting dissection in 11. Provisional spot stenting was done using the Zilver PTX DES. Clinical improvement was observed in all cases. After 24-month follow-up all patients were alive and in good clinical condition. One- and 2-year primary patency rates were 93.3% and 92.9%, respectively; secondary patency was 100%. Restenosis required reintervention in 2 cases. No local or systemic complications or toxicity were observed due to the use of a double dose of paclitaxel. No significant increase in any inflammation marker was observed in the perioperative period, and no aneurysm formation was seen over 24 months of follow-up. Conclusion: Combined DCB plus DES therapy seems to be safe and correlated with high primary patency following suboptimal angioplasty. Larger studies are required to confirm the safety and efficacy of this approach.

Sign in / Sign up

Export Citation Format

Share Document